Scala Biodesign Partners with Ribbon Bio to Advance Enzyme Innovation with Next-Generation Technologies
We’re excited to share that our portfolio company Scala Biodesign has announced a new partnership with Ribbon Bio to advance enzyme innovation and accelerate next-generation DNA synthesis technologies. This collaboration brings together two women-led biotechnology companies at the forefront of computational design and enzymatic synthesis—uniting their strengths to deliver more powerful molecular tools to customers across the life sciences.
Ribbon Bio is transforming DNA synthesis with its MiroSynth™ platform, a system that uses enzymes to assemble long, accurate DNA molecules for synthetic biology and biopharma applications. Scala Biodesign complements this capability with ScalaOS, its computational platform that designs enzymes with enhanced stability, performance, and suitability for demanding applications. By combining enzyme engineering with precision DNA assembly, the partnership will help customers conduct research more quickly, efficiently, and cost-effectively.
“We are thrilled to be working with the team at Scala Biodesign as we are always seeking ways to challenge the limits of DNA synthesis,” said Jodi Barrientos, CEO of Ribbon Bio. “We are confident that the more powerful enzymes behind our algorithm-driven design of synthetic DNA can translate into speedier delivery, stronger performance, and better outcomes for our customers.”
“At Scala Biodesign, our mission is to provide enzymes that are more stable, efficient, and ready for demanding applications,” said Dr. Ravit Netzer, CEO and Co-founder of Scala Biodesign. “Seeing these designs perform within Ribbon’s precision system highlights the potential of computational enzyme design to deliver immediate value.”
The collaboration marks a major step forward in demonstrating how computational protein design and next-generation DNA synthesis can work together to deliver real-world benefits, including improved accuracy, shorter development times, and expanded access to advanced tools in a rapidly evolving biotech landscape.
The two companies plan to launch a series of joint programs in the coming months aimed at advancing enzymatic DNA capabilities for biopharma and broader biotechnology customers.
Read the full announcement.